Program
alpha 1-Antitrypsin
Also written as “Alpha-1 MP”, “GLASSIA” and “Alpha1-proteinase inhibitor”.
Its studies are mostly in alpha 1-Antitrypsin Deficiency · Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema · Graft vs Host Disease · Diabetes Mellitus, Type 1, led by 4 companies.
Drug pageAlpha 1-Antitrypsin: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grifolsits history only | 131 open or running | phase 3since Feb 20, 2006 | Sep 12, 2005 | Sep 2028phase 3 · NCT02796937 |
| Takedaits history only | 70 open or running | phase 4since Nov 3, 2006 | Nov 3, 2006 | none ahead |
| CSL | 31 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | Sep 15, 2033phase 4 · NCT07326592 |
| Kamadaits history only | 30 open or running | phase 3since Dec 17, 2019 | Feb 24, 2011 | none ahead |
Also a collaborator on its studies: Baxalta Innovations GmbH, now part of Shire.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CSL only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 2, 2005First study: phase 4 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT00261833 · 180 enrolled · United States, Australia, Canada and more
- Nov 15, 2019Phase 3 study in Graft vs Host DiseaseNCT04167514 · 136 enrolled · United States
- Jan 7, 2026Phase 4 study in alpha 1-Antitrypsin DeficiencyNCT07326592 · 270 planned · Denmark
Ahead
- Sep 15, 2033Primary completion: phase 4 study in alpha 1-Antitrypsin DeficiencyNCT07326592
TargetBeta
“Leukocyte elastase inhibitor”ChEMBL 37, by rule
Studies
All 3 CSL leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07326592alpha 1-Antitrypsin Deficiency · Denmark | 4 | Recruiting | Sep 15, 2033 | 270 |
| NCT04167514Graft vs Host Disease · United States | 3 | Completed | Sep 11, 2023 | 136 |
| NCT00261833alpha 1-Antitrypsin Deficiency · United States, Australia, Canada and more | 4 | Completed | Sep 2012 | 180 |
How it is read
Names in the registry
- “Alpha-1 MP”, 5 entries
- “GLASSIA”, 2 entries
- “Alpha1-proteinase inhibitor”, 2 entries
- “Alpha1-Proteinase Inhibitor (Human)”, 2 entries
- “CE1226”, 1 entry
Conditions, from the studies’ own filings
- alpha 1-Antitrypsin Deficiency, 12 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Pulmonary Emphysema, 2 studies
- Graft vs Host Disease, 2 studies
- Diabetes Mellitus, Type 1, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.